Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
基本信息
- 批准号:7387425
- 负责人:
- 金额:$ 26.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisArthritisAutoimmune DiseasesBindingCell Adhesion InhibitionCell DeathCell surfaceCellsCollagen ArthritisCultured CellsCytoplasmCytoplasmic TailCytotoxic agentDoseDrug Delivery SystemsEndosomesEpithelial CellsEvaluationFigs - dietaryFluoresceinFluoresceinsFolic AcidGoalsHumanIn VitroIntegrinsIntercellular adhesion molecule 1IsothiocyanatesKineticsLabelLeukocytesLinkLocalizedLymphocyte Function-Associated Antigen-1MeasuresMediatingMembraneMethodsMethotrexateModelingMusPeptidesPharmaceutical PreparationsProcessProcess MeasureProductionProteinsRecyclingResearch DesignResearch PersonnelResistanceRheumatoid ArthritisRoleSLC19A1 geneSignal TransductionSurfaceSystemT-Cell ActivationT-Cell LeukemiaT-LymphocyteToxic effectcrosslinkcytohesin-1cytokinecytotoxicityfolate-binding proteinin vivo Modelleukemiamouse modelprogramsreceptorresponseuptake
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to understand the mechanism of internalization of integrins and their utility for targeting drugs to specific cells. The short-term objective of this proposal is to study the mechanism of internalization of LFA-1 on T cells and to utilize this mechanism for targeting drugs to leukocytes. The central hypothesis is that an ICAM-1-derived peptide (cIBR) can bind to and be internalized by LFA-1. Therefore, a cytotoxic drug (methotrexate, MTX) will be linked with cIBR peptide to give MTX-cIBR conjugate; this conjugate will have dual functions: (a) to inhibit T-cell activation via inhibition of the cell adhesion signal and (b) to induce T-cell death by internalizing MTX. The MTX-cIBR conjugate has selective toxicity for LFA-1-expressing T cells but not LFA-1-deficient KB epithelial cells. MTXcIBR conjugate suppressed rheumatoid arthritis in the collagen-induced arthritis (CIA) mouse model better than MTX alone. Therefore, the first objective is to evaluate the mechanism of suppression of arthritis by MTX-cIBR conjugate (Specific Aim 1). The mechanism of MTX-cIBR conjugate in altering the activation of T cells from Th1 to Th2 response in the CIA mouse model will be elucidated. In addition, the long-term kinetic effects of MTX-cIBR on the T-cell commitment in the CIA mouse model will be determined. Secondly, the internalization of MTX-cIBR or FITC-cIBR conjugates will be released by LFA-1 in the cytoplasm; alternatively, it could (a) remain with the endosome, (b) be recycled to the cell surface, or (c) be targeted to other membrane compartments. Therefore, the internalization process and localization of these conjugates will be determined (Specific Aim 2). Thirdly, the internalization of MTX-cIBR may also be via reduced folate carrier (RFC) or membrane folate binding protein (mFBP). In Specific Aim 3, MTX-cIBR will be compared using wild type and RFC-deficient mouse leukemia T cells. In addition, this conjugate will be compared with MTX in mFBP over-expressing leukemia mouse cells in the presence and absence of folic acid. Finally, the exact mechanism of the LFA-1 internalization and the identity of other proteins that are involved in this process are not well understood. In Specific Aim 4, cIBR peptide will be modified and cross-linked to LFA-1 on activated T cells; the crosslink will be isolated along with proteins that interact with LFA-1. These isolated proteins will be identified.
描述(由申请人提供):本提案的长期目标是了解整合素的内化机制及其用于将药物靶向至特定细胞的效用。该提案的短期目标是研究LFA-1在T细胞上的内化机制,并利用该机制将药物靶向白细胞。核心假设是ICAM-1衍生肽(cIBR)可以结合LFA-1并被其内化。因此,细胞毒性药物(甲氨蝶呤,MTX)将与cIBR肽连接,得到MTX-cIBR缀合物;该缀合物将具有双重功能:(a)通过抑制细胞粘附信号抑制T细胞活化和(B)通过内化MTX诱导T细胞死亡。MTX-cIBR缀合物对表达LFA-1的T细胞具有选择性毒性,但对LFA-1缺陷型KB上皮细胞不具有选择性毒性。MTX cIBR缀合物在胶原诱导的关节炎(CIA)小鼠模型中比单独MTX更好地抑制类风湿性关节炎。因此,第一个目的是评价MTX-cIBR偶联物抑制关节炎的机制(特异性目的1)。将阐明MTX-cIBR缀合物在CIA小鼠模型中将T细胞活化从Th 1应答改变为Th 2应答的机制。此外,还将确定MTX-cIBR对CIA小鼠模型中T细胞定型的长期动力学影响。其次,MTX-cIBR或FITC-cIBR缀合物的内化将通过细胞质中的LFA-1释放;或者,其可以(a)保留在内体中,(B)再循环至细胞表面,或(c)靶向其他膜隔室。因此,将确定这些缀合物的内化过程和定位(具体目标2)。第三,MTX-cIBR的内化也可以通过还原叶酸载体(RFC)或膜叶酸结合蛋白(mFBP)。在特定目标3中,将使用野生型和RFC缺陷型小鼠白血病T细胞比较MTX-cIBR。此外,将在存在和不存在叶酸的情况下,在mFBP过表达白血病小鼠细胞中比较该缀合物与MTX。最后,LFA-1内化的确切机制和参与该过程的其他蛋白质的身份尚未得到很好的理解。在特定目标4中,cIBR肽将被修饰并与活化T细胞上的LFA-1交联;交联将与与LFA-1相互作用的蛋白质一起沿着分离。将鉴定这些分离的蛋白质。
项目成果
期刊论文数量(23)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Rapid identification of fluorochrome modification sites in proteins by LC ESI-Q-TOF mass spectrometry.
- DOI:10.1021/bc100560c
- 发表时间:2011-07-20
- 期刊:
- 影响因子:4.7
- 作者:Manikwar, Prakash;Zimmerman, Tahl;Blanco, Francisco J.;Williams, Todd D.;Siahaan, Teruna J.
- 通讯作者:Siahaan, Teruna J.
Vaccinelike and prophylactic treatments of EAE with novel I-domain antigen conjugates (IDAC): targeting multiple antigenic peptides to APC.
- DOI:10.1021/mp300440x
- 发表时间:2013-01-07
- 期刊:
- 影响因子:4.9
- 作者:Büyüktimkin B;Manikwar P;Kiptoo PK;Badawi AH;Stewart JM Jr;Siahaan TJ
- 通讯作者:Siahaan TJ
Sequence recognition of alpha-LFA-1-derived peptides by ICAM-1 cell receptors: inhibitors of T-cell adhesion.
ICAM-1 细胞受体对 α-LFA-1 衍生肽的序列识别:T 细胞粘附抑制剂。
- DOI:10.1111/j.1747-0285.2007.00549.x
- 发表时间:2007
- 期刊:
- 影响因子:3
- 作者:Yusuf-Makagiansar,Helena;Yakovleva,TatyanaV;Tejo,BimoA;Jones,Karen;Hu,Yongbo;Verkhivker,GennadyM;Audus,KennethL;Siahaan,TerunaJ
- 通讯作者:Siahaan,TerunaJ
A peptide from the beta-strand region of CD2 protein that inhibits cell adhesion and suppresses arthritis in a mouse model.
来自 CD2 蛋白 β 链区域的肽,可抑制小鼠模型中的细胞粘附并抑制关节炎。
- DOI:10.1111/j.1747-0285.2010.01001.x
- 发表时间:2010
- 期刊:
- 影响因子:3
- 作者:Satyanarayanajois,SeetharamaD;Büyüktimkin,Barlas;Gokhale,Ameya;Ronald,Sharon;Siahaan,TerunaJ;Latendresse,JohnR
- 通讯作者:Latendresse,JohnR
Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.
- DOI:10.1016/j.jneuroim.2013.07.009
- 发表时间:2013-10-15
- 期刊:
- 影响因子:3.3
- 作者:Badawi, Ahmed H.;Siahaan, Teruna J.
- 通讯作者:Siahaan, Teruna J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERUNA J. SIAHAAN其他文献
TERUNA J. SIAHAAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERUNA J. SIAHAAN', 18)}}的其他基金
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
- 批准号:
10549826 - 财政年份:2022
- 资助金额:
$ 26.46万 - 项目类别:
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
- 批准号:
10363417 - 财政年份:2022
- 资助金额:
$ 26.46万 - 项目类别:
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
用 ApoE2 重塑 ApoE4 和阿尔茨海默病大脑
- 批准号:
10812094 - 财政年份:2022
- 资助金额:
$ 26.46万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8320154 - 财政年份:2011
- 资助金额:
$ 26.46万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8492187 - 财政年份:2011
- 资助金额:
$ 26.46万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8162174 - 财政年份:2011
- 资助金额:
$ 26.46万 - 项目类别:
Modulating the BBB to Improve Drug Delivery to the Brain
调节血脑屏障以改善药物向大脑的输送
- 批准号:
8666676 - 财政年份:2011
- 资助金额:
$ 26.46万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
6968983 - 财政年份:2005
- 资助金额:
$ 26.46万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
7209818 - 财政年份:2005
- 资助金额:
$ 26.46万 - 项目类别:
Targeting and Internalization Mechanism of LFA-1
LFA-1的靶向和内化机制
- 批准号:
7082012 - 财政年份:2005
- 资助金额:
$ 26.46万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 26.46万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 26.46万 - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
$ 26.46万 - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 26.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
$ 26.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 26.46万 - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
$ 26.46万 - 项目类别:
Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 26.46万 - 项目类别:
Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
$ 26.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
$ 26.46万 - 项目类别: